Of cos .. the company prospect is not bright enough yet ..... and this is why the share price is so "chia luck". If is bright and everyone can see ... then it won't be 0.36 now liao .... looking on TA ... the chart still looks ok right now to me .....

On the CE stuff..... getting the CE doesn't mean that the company will fly straight away, it still need time to expand the biz ..... and make it brighter to outshine the rest.

After all, this is a venture capitalist counter, thus i consider it as a high risk counter as you can tell from the volatility of the share price especially when this type of company has yet show its profitability and potential. But with the CE mark and looking ahead on BIG business development ... it is very much better off than last time. 

On the management, it is better that they talk more, make some noise and do more marketing ..... so that people can hear them .....

This is why i said this 3rd quarter results and the fnal closing on this FY09 is a guidance on how BIG is doing on its Biz development and whether the "prospect" is still intact for FY10 and so on .....

If the CEO can turn BIG into BLACK in FY10 ... then i think the price will eventually catch up very fast ......  If not ... then it will be dimmer ... hahaha ... and dump liao ...

Anyway, staking in BIG is like playing "BIG or SMALL" ...... when it goes up it goes very fast and then, drop also drop lagi fast .....

Each to his own risk level .... to me this type of counter is very interesting and fun .... and definetly not for those faint hearted .....

Cheers to all.

Above not an inducement to trade.

Bio is my Ox year 1st Angpow stock.... TA nice and vested at 0.355.... Ready to take off !!! 

www.sgsharetalk.com/forum

From Angioplasty.org - For info.

January 23, 2009 -- In an announcement today, Xtent Inc. (NASDAQ: XTNT) located in Menlo Park, California, stated that it is engaging the services of an investment bank to help the company pursue strategic alternatives, possible sale of some or all of the company's assets, or other type of acquisition. And of it 121 employees, all but nine have received termination notices, effective March 23.

 

CEO and President, Gregory D. Casciaro, stated:

 

"Given the continued challenges faced in the capital markets, we believe it is in the best interests of the shareholders to consider strategic options. We remain confident in the benefits of customizable stenting and are assessing all viable options available to us in order to maximize the value of our assets. Effective immediately, we are executing plans to reduce activities and costs to a critical minimum, including a significant reduction in headcount in order to preserve cash and flexibility."

 

When Xtent went public in two years ago, its stock traded at over $16. Today Xtent closed at $.20, a mere 1% of its original value. However, the company's situation has much to do with the current economic landscape and shrinking of credit, and less to do with the company's main product: the customizable stent

One difficulty the interventional cardiologists face is choosing the proper length stent for a blockage. Too short a stent doesn't completely cover the diseased area, a situation which become high risk for increased cell growth around its edges and subsequent restenosis (blockage). Likewise, if the stent is too long, metal is being placed in too large a healthy section of the artery, something which also increases the risk of blockage. With the Xtent, physicians can tailor, on the spot, the length of the stent during the procedure. The Xtent is a cobalt-chromium metal stent, covered with a biodegradable coating which eludes Biolimus A9™, a drug which suppresses excess cellular growth, licensed from Biosensors.

 

Article from WSJ. - For Info

By JON KAMP

A tough financing environment caught up to development-stage medical company Xtent Inc., which has a heart stent in the works but said Friday it may lay off nearly all its workers while it looks for a strategic deal.

Xtent's struggles are familiar among the ranks of pre-revenue medical device and biotechnology companies, where expensive studies are needed to prove technology works. The struggles are compounded with the current scarcity of financing: There is little appetite among investors these days for high-risk, high-reward propositions. While big players could easily snap up these cheap companies, deal-making has yet to really take off.

Xtent, which went public about two years ago at $16, closed Friday at 20 cents a share, down 1 cent. That puts the market valuation at less than $5 million, which would look like bus fare to the four big players in the stent business: Johnson & Johnson, Boston Scientific Corp., Abbott Laboratories and Medtronic Inc.

All of the stent makers have been doing some deals lately. Among them, Medtronic and Boston Scientific have picked up some small companies that make devices to treat a heart-rhythm problem, J&J bought a breast-implant maker and Abbott is buying eye-care company Advanced Medical Optics Inc.

For now, Xtent has announced plans for draconian layoffs; 112 of 121 employees will be gone effective March 23, unless an investor or buyer swoops in.

Xtent Chief Executive Gregory Casciaro said Friday there has been a good reaction thus far regarding potential strategic options. He pointed out that Xtent's technology -- which allows stents to be cut to size while in blood vessels -- could also work for companies interested in long stents to treat clogged leg arteries.

Xtent has been working to gain approval for its product in Europe, but the process has been slower than hoped. Xtent needs more money to operate in Europe even if regulators do approve its stent soon, Mr. Casciaro said.

Pfizer to acquire rival Wyeth for $68 bln

NEW YORK (AFP) - - US drug manufacturer Pfizer Inc. will acquire rival Wyeth for 68 billion dollars, making it the largest pharmaceutical takeover deal in nearly a decade, the two companies announced early Monday.